Provectus Biopharma (PVCT) Reports Q1 Loss of $0.04/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Provectus Biopharmaceuticals, Inc. Reports First Quarter 2016 Financial Results
May 10, 2016 6:12 PM EDTKNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company (Provectus or the "Company), today announced its financial results for the first quarter 2016 ended March 31, 2016.
First Quarter Results and Balance Sheet Highlights
Our cash and cash equivalents were $9,760,997 at March 31, 2016, compared with $14,178,902 at December 31, 2015. The... More
